Flex Pharma's cramp study fails, shares plunge; FDA makes Egalet wait on pain drug
Shares of Flex Pharma $FLKS took a nasty hit yesterday as the biotech tried to explain away a preliminary conclusion that their lead drug, FLX-787, failed a study for preventing leg cramps. If you exclude data from one of the three sites you get a significant result, said the biotech. That argument rarely fares well, and Christoph Westphal’s company wasn’t able to make much headway against the negative reaction.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.